newsfilter
← Latest News
GlobeNewswire·

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 – – Completed upsized IPO with gross proceeds of